Global Coalition for Adaptive Research
The Global Coalition for Adaptive Research (GCAR) is a 501(c)(3) nonprofit organization dedicated to accelerating the discovery and development of treatments for patients with rare and deadly diseases through innovative clinical trials, including master protocols and adaptive platform trials.
Industries
N/A
Nr. of Employees
small (1-50)
Global Coalition for Adaptive Research
700 Larkspur Landing Circle, Suite 199, Larkspur, CA 94939-1754
Awards
GCAR: Experienced and Qualified Sponsor to Support PTSD Adaptive Platform Trial
Funding (ceiling)
$1,215,841.77
Award Year
2024
Products
Registrational-intent Phase 2/3 adaptive platform trial for glioblastoma
A multi-arm adaptive Phase 2/3 platform trial for glioblastoma that evaluates multiple investigational therapies and biomarker-defined subpopulations using adaptive randomization and a shared control, with the intent that generated data may support regulatory submissions.
Multifactorial adaptive platform sub-study for severe respiratory infection
A multifactorial randomized adaptive platform sub-study testing multiple treatment domains and combinations in hospitalized patients with severe respiratory infection, using frequent interim analyses and multi-domain randomization.
Adaptive platform trial for ovarian cancer with re-enrollment and longitudinal biomarker collection
An adaptive multi-arm platform to evaluate multiple drugs and combinations against standard of care in newly diagnosed and recurrent ovarian cancer, allowing interventions to enter or exit over time and enabling re-enrollment and longitudinal molecular data collection.
Umbrella master protocol for biliary tract cancers with genomic eligibility
An umbrella master protocol to concurrently evaluate multiple experimental therapies in biliary tract cancers using genomic testing to assign patients to targeted therapy arms and common endpoints.
Pancreatic cancer master protocol leveraging shared platform infrastructure
A master protocol developed with disease-focused partners to streamline operations, expand site access, and evaluate multiple regimens in metastatic pancreatic cancer using shared platform infrastructure.
Platform-basket trial for neurofibromatosis manifestations
A randomized multi-arm platform-basket study evaluating investigational interventions across multiple clinical manifestations of a genetic disease, supporting phase 1/2 assessments with response-specific endpoints.
Registrational-intent Phase 2/3 adaptive platform trial for glioblastoma
A multi-arm adaptive Phase 2/3 platform trial for glioblastoma that evaluates multiple investigational therapies and biomarker-defined subpopulations using adaptive randomization and a shared control, with the intent that generated data may support regulatory submissions.
Multifactorial adaptive platform sub-study for severe respiratory infection
A multifactorial randomized adaptive platform sub-study testing multiple treatment domains and combinations in hospitalized patients with severe respiratory infection, using frequent interim analyses and multi-domain randomization.
Adaptive platform trial for ovarian cancer with re-enrollment and longitudinal biomarker collection
An adaptive multi-arm platform to evaluate multiple drugs and combinations against standard of care in newly diagnosed and recurrent ovarian cancer, allowing interventions to enter or exit over time and enabling re-enrollment and longitudinal molecular data collection.
Umbrella master protocol for biliary tract cancers with genomic eligibility
An umbrella master protocol to concurrently evaluate multiple experimental therapies in biliary tract cancers using genomic testing to assign patients to targeted therapy arms and common endpoints.
Pancreatic cancer master protocol leveraging shared platform infrastructure
A master protocol developed with disease-focused partners to streamline operations, expand site access, and evaluate multiple regimens in metastatic pancreatic cancer using shared platform infrastructure.
Platform-basket trial for neurofibromatosis manifestations
A randomized multi-arm platform-basket study evaluating investigational interventions across multiple clinical manifestations of a genetic disease, supporting phase 1/2 assessments with response-specific endpoints.
Expertise Areas
- Adaptive platform and master protocol trial implementation
- Adaptive statistical methodology and Bayesian designs
- Clinical trial operations and global site activation
- Regulatory sponsorship and registration-oriented trial support
Key Technologies
- Master protocol frameworks
- Adaptive platform trial designs
- Bayesian statistical methods
- Adaptive randomization
News & Updates
AstraZeneca’s AZD1390 to Join GBM AGILE, a Registrational-Intent Phase 2/3 Adaptive Platform Trial for Patients with Glioblastoma. Recruitment of patients expected to begin by Q2 2025.
AstraZeneca’s AZD1390 to Join GBM AGILE, a Registrational-Intent Phase 2/3 Adaptive Platform Trial for Patients with Glioblastoma. Recruitment of patients expected to begin by Q2 2025.